Results 81 to 90 of about 2,363,919 (190)
Molecular Medicine Reports, 2014 Cancer cells preferentially catalyze glucose through the glycolytic pathway in the presence of adequate oxygen. This phenomenon is known as the Warburg effect. As is the case with numerous cancer therapeutic agents, resistance remains a significant problem when using Taxol® to treat malignancies.
Qi, Xie +6 more
openaire +3 more sources
Molecular Medicine Reports, 2015 Malignant gliomas, which comprise the most common type of primary malignant brain tumor, are associated with a poor prognosis and quality of life. Paclitaxel (Taxol) and temozolomide (TMZ) are Food and Drug Administration‑approved anticancer agents, which are known to have therapeutic applications in various malignancies.
Ding-Guo, Guan +3 more
openaire +3 more sources
Genome-wide DNA methylation analysis of breast cancer MCF-7 / Taxol cells with MeDIP-Seq.
PLoS ONE, 2020 Breast cancer (BC) is the most frequently diagnosed tumor in women worldwide. Although the combination of surgery and Taxol chemotherapy can achieve a certain therapeutic effect, patients often develop drug-resistance, resulting in a poor prognosis ...
Ying Shi +4 more
doaj +1 more source
lncRNA-DANCR Promotes Taxol Resistance of Prostate Cancer Cells through Modulating the miR-33b-5p-LDHA Axis. [PDF]
Dis Markers, 2022 Wang YY, Chen C.
europepmc +1 more source
Mcl-1 stabilization confers resistance to taxol in human gastric cancer
Oncotarget, 2017 Taxol has been extensively used as an antineoplastic drug to treat human gastric cancer. However, the acquired drug resistance invariably develops and greatly limits the therapeutic efficacy of Taxol. Identification of the underlying resistance mechanisms may inform the development of new therapies of gastric cancers to Taxol treatment.
Shuang, Wu +4 more
openaire +3 more sources
Activity of liposomal taxol against breast cancer cells / by Melanie Heney. [PDF]
, 2007 Taxol (paclitaxel) is one of the most effective chemotherapeutic agents used for the treatment of multiple cancers, including breast, ovarian, and, non-small-cell lung cancer.
Heney, Melanie A.
core
CD133+/ABCC5+ cervical cancer cells exhibit cancer stem cell properties
HeliyonObjective: This study explores the correlation between Forkhead box M1 (FOXM1) and ATP-binding cassette subfamily C member 5 (ABCC5) in relation to paclitaxel resistance in cervical cancer. It aims to identify potential cervical cancer stem cell markers,
Lin He +7 more
doaj +1 more source
Circular RNA hsa_circ_0011298 enhances Taxol resistance of non-small cell lung cancer by regulating miR-486-3p/CRABP2 axis. [PDF]
J Clin Lab Anal, 2022 Wu Y, Xie J, Wang H, Hou S, Feng J.
europepmc +1 more source
Taxol: Mechanisms of action and resistance
, 1998 Taxol is an antitumor agent that has been approved for the treatment of ovarian, breast and lung carcinomas. The major cellular target for Taxol is beta-tubulin. Taxol stabilizes microtubules leading to a mitotic block and apoptosis.
Burkhart, Catherine Alyce
core
BMC CancerBackground The main challenge in treating ovarian cancer is chemotherapy resistance. Previous studies have shown that PAK2 is highly expressed in various cancers.
Ting Shuang +4 more
doaj +1 more source